Version in force 1 May 2026

Previous version, in force 1 September 2025 02008R1272-20250901 → this version, in force 1 May 2026 02008R1272-20260501

compared line by line: this provision is too large to compare word by word, so a marked line is a line that changed somewhere

ANNEX VI Harmonised classification and labelling for certain hazardous substances Part 1 of this Annex provides an introduction to the list of harmonised classification and labelling, including information listed for each entry and related classifications and hazard statements in Table 3. … 466 unchanged lines … Dgr H250 H314 A 005-005-00-1 trimethyl borate 204-468-9 121-43-7 Flam. Liq. 3 Acute Tox. 4 * H226 Repr. 1B Acute Tox. 4* H226 H360FD H312 GHS02 GHS08 GHS07 Wng H226 H312 005-006-00-7 dibutyltin hydrogen borate 401-040-5 75113-37-0 Repr. 1B Dgr H226 H360FD H312 11 005-006-00-7 dibutyltin hydrogen borate 401-040-5 75113-37-0 Repr. 1B Muta. 2 STOT RE 1 Acute Tox. 4 * … 250 unchanged lines … disodium octaborate tetrahydrate [2] 234-541-0 [1] 234-541-0 [2] 12008-41-2 [1] 12280-03-4 [2] Repr. 1B H360FD GHS08 Dgr H360FD 006-001-00-2 carbon monoxide 211-128-3 630-08-0 Flam. Gas 1 Dgr H360FD 005-023-00-X perboric acid (H3BO2(O2)), monosodium salt trihydrate [1] perboric acid, sodium salt, tetrahydrate [2] perboric acid (HBO(O2)), sodium salt, tetrahydrate [3] sodium peroxoborate, hexahydrate [4] 239-172-9 [1] 234-390-0 [2] - [3] - [4] 13517-20-9 [1] 37244-98-7 [2] 10486-00-7 [3] - [4] Repr. 1B Acute Tox. 4 STOT SE 3 Eye Dam. 1 H360FD H332 H335 H318 GHS08 GHS05 GHS07 Dgr H360FD H332 H335 H318 inhalation: ATE = 1,2 mg/L (dusts or mists) Eye Dam. 1; H318: C ≥ 36 % Eye Irrit. 2; H319: 22 % ≤ C < 36 % 11 005-024-00-5 sodium peroxometaborate 231-556-4 7632-04-4 Ox. Sol. 2 Repr. 1B Acute Tox. 3 Acute Tox. 4 STOT SE 3 Eye Dam. 1 H272 H360FD H331 H302 H335 H318 GHS03 GHS08 GHS06 GHS05 Dgr H272 H360FD H331 H302 H335 H318 inhalation: ATE = 0,62 mg/L (dusts or mists) oral: ATE = 730 mg/kg bw Eye Dam. 1; H318: C ≥ 22 % Eye Irrit. 2; H319: 14 % ≤ C < 22 % 11 006-001-00-2 carbon monoxide 211-128-3 630-08-0 Flam. Gas 1 Press. Gas Repr. 1A Acute Tox. 3 * … 1,076 unchanged lines … GHS09 Dgr H318 H334 H410 M=100 007-001-00-5 ammonia, anhydrous 231-635-3 7664-41-7 Flam. Gas 2 H410 M=100 006-104-00-2 multi-walled carbon tubes (synthetic graphite in tubular shape) with a geometric tube diameter range ≥ 30 nm to < 3 μm and a length ≥ 5 μm and aspect ratio > 3:1, including multi-walled carbon nanotubes, MWC(N)T — — Carc. 1B STOT RE 1 H350i H372 (lung)(inhalation) GHS08 Dgr H350i H372 (lung)(inhalation) STOT RE 1; H372: C ≥ 1 %; STOT RE 2; H373: 0,1 % ≤ C < 1 % 007-001-00-5 ammonia, anhydrous 231-635-3 7664-41-7 Flam. Gas 2 Press. Gas Acute Tox. 3 * Skin Corr. 1B … 2,978 unchanged lines … H331 H410 U 016-022-00-9 ethanethiol; ethyl mercaptan 200-837-3 75-08-1 Flam. Liq. 2 Acute Tox. 4 * ethyl mercaptan 200-837-3 75-08-1 Flam. Liq. 1 Acute Tox. 3 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 H225 H332 Aquatic Chronic 1 H224 H331 H302 H400 H410 GHS02 GHS07 GHS06 GHS09 Dgr H225 H332 H410 016-023-00-4 dimethyl sulphate 201-058-1 77-78-1 Carc. 1B Dgr H224 H331 H302 H410 inhalation: ATE = 7,1 mg/L (vapours) oral: ATE = 680 mg/kg bw 016-023-00-4 dimethyl sulphate 201-058-1 77-78-1 Carc. 1B Muta. 2 Acute Tox. 2 * Acute Tox. 3 * … 2,808 unchanged lines … Wng H302 H410 oral: ATE = 500 mg/kg bw M = 10 M = 10 029-019-01-X copper flakes (coated with aliphatic acid) — — Acute Tox. 3 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 H331 M = 10 029-019-01-X copper flakes (coated with aliphatic acid) Acute Tox. 3 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 H331 H302 H319 H400 H410 GHS06 GHS09 Dgr H331 H302 H319 H410 inhalation: ATE = 0,733 mg/l (dusts or mists) oral: ATE = 500 mg/kg bw H410 inhalation: ATE = 0,733 mg/l (dusts or mists) oral: ATE = 500 mg/kg bw M = 10 M = 10 029-020-00-8 copper(II) carbonate—copper(II) hydroxide (1:1) 235-113-6 12069-69-1 Acute Tox. 4 M = 1 029-020-00-8 copper(II) carbonate—copper(II) hydroxide (1:1) 235-113-6 12069-69-1 Acute Tox. 4 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 … 79 unchanged lines … H318 H410 oral: ATE = 360 mg/kg bw M = 1 M = 1 030-001-00-1 zinc powder — zinc dust (pyrophoric) 231-175-3 7440-66-6 Water-react. 1 M = 1 029-026-00-0 copper [specific surface area > 0,67 mm2/mg] 231-159-6 7440-50-8 Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 M = 10 M = 1 030-001-00-1 zinc powder — zinc dust (pyrophoric) 231-175-3 7440-66-6 Water-react. 1 Pyr. Sol. 1 Aquatic Acute 1 Aquatic Chronic 1 H260 … 386 unchanged lines … H315 H318 H410 M = 100 M = 100 048-001-00-5 cadmium compounds, with the exception of cadmium sulphoselenide (xCdS.yCdSe), reaction mass of cadmium sulphide with zinc sulphide (xCdS.yZnS), reaction mass of cadmium sulphide with mercury sulphide (xCdS.yHgS), and those specified elsewhere in this Annex — — Acute Tox. 4 * M = 100 047-004-00-9 silver massive: [particle diameter ≥ 1 mm] 231-131-3 7440-22-4 Repr. 2 STOT RE 2 H361f H373 (nervous system) GHS08 Wng H361f H373 (nervous system) 047-005-00-4 silver powder: [particle diameter > 100 nm < 1 mm] 231-131-3 7440-22-4 Repr. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H361f H373 (nervous system) H400 H410 GHS08 GHS09 Wng H361f H373 (nervous system) H410 M = 10 M = 10 047-006-00-X silver nano: [particle diameter > 1 nm ≤ 100 nm] 231-131-3 7440-22-4 Repr. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H361f H373 (nervous system) H400 H410 GHS08 GHS09 Wng H361f H373 (nervous system) H410 M = 1000 M = 1000 048-001-00-5 cadmium compounds, with the exception of cadmium sulphoselenide (xCdS.yCdSe), reaction mass of cadmium sulphide with zinc sulphide (xCdS.yZnS), reaction mass of cadmium sulphide with mercury sulphide (xCdS.yHgS), and those specified elsewhere in this Annex — — Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Aquatic Acute 1 … 2,125 unchanged lines … H410 601-037-00-0 n-hexane 203-777-6 110-54-3 Flam. Liq. 2 Repr. 2 Asp. Tox. 1 STOT RE 2 * STOT SE 3 STOT RE 1 Skin Irrit. 2 STOT SE 3 Aquatic Chronic 2 H225 H361f *** H304 H373 ** H361f*** H304 H336 H372 (nervous system) H315 H336 H411 GHS02 GHS08 GHS07 GHS09 Dgr H225 H361f *** H304 H373 ** H315 H361f*** H304 H336 H411 STOT RE 2; H373: C ≥ 5 % 601-041-00-2 dibenz[a,h]anthracene 200-181-8 53-70-3 Carc. 1B H372 (nervous system) H315 H411 601-041-00-2 dibenz[a,h]anthracene 200-181-8 53-70-3 Carc. 1B Aquatic Acute 1 Aquatic Chronic 1 H350 H400 … 3,592 unchanged lines … H410 GHS08 GHS09 Wng H373 (teeth, bones) H410 M = 1 604-001-00-2 phenol; carbolic acid; monohydroxybenzene; phenylalcohol 203-632-7 108-95-2 Muta. 2 H410 M = 1 603-247-00-8 reaction mass of 1,3-dioxan-5-ol and 1,3-dioxolan-4-ylmethanol — — Repr. 1B H360Df GHS08 Dgr H360Df 604-001-00-2 phenol; carbolic acid; monohydroxybenzene; phenylalcohol 203-632-7 108-95-2 Muta. 2 Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Skin Corr. 1B H341 … 304 unchanged lines … GHS09 Wng H302 H319 H410 604-020-00-6 2-phenylphenol (ISO)biphenyl-2-ol; 2-hydroxybiphenyl; 201-993-5 90-43-7 Eye Irrit. 2 STOT SE 3 Skin Irrit. 2 Aquatic Acute 1 H319 H335 H315 H400 GHS07 H410 604-020-00-6 biphenyl-2-ol; 2-phenylphenol; 2-hydroxybiphenyl 201-993-5 90-43-7 Carc. 2 Skin Corr. 1 Eye Dam. 1 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1 H351 H314 H318 H317 H400 H410 GHS08 GHS05 GHS07 GHS09 Wng H319 H335 H315 H400 604-021-00-1 sodium 2-biphenylate; 2-phenylphenol, sodium salt 205-055-6 132-27-4 Acute Tox. 4 * STOT SE 3 Dgr H351 H314 H317 H410 M = 1 M = 1 604-021-00-1 sodium 2-biphenylate; 2-phenylphenol, sodium salt 205-055-6 132-27-4 Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 H302 … 541 unchanged lines … Aquatic Chronic 1 H400 H410 GHS09 Wng H410 M = 1 M = 10 605-001-00-5 formaldehyde …% 200-001-8 50-00-0 Carc. 1B Muta. 2 Acute Tox. 3* Acute Tox. 3* Acute Tox. 3* M = 10 605-001-00-5 formaldehyde … % 200-001-8 50-00-0 Carc. 1B Muta. 2 Acute Tox. 2 Acute Tox. 4 Skin Corr. 1B Skin Sens. 1 H350 Skin Sens. 1A H350 H341 H301 H311 H331 H330 H302 H314 H317 GHS08 GHS06 GHS05 Dgr H350 H341 H301 H311 H331 H330 H302 H314 H317 * Skin Corr. 1B; H314: C ≥25 % Skin Irrit. 2; H315: 5 % ≤C < 25 % Eye Irrit. 2; H319: 5 % ≤ C <25 % STOT SE 3; H335: C ≥ 5 % SkinSens.; H317: C ≥ 0,2 % B, D H317 EUH071 inhalation: ATE = 100 ppmV (gases) oral: ATE = 500 mg/kg bw STOT SE 3; H335: C ≥ 5 % Skin Corr. 1B; H314: C ≥ 25 % Skin Irrit. 2; H315: 5 % ≤ C < 25 % Eye Irrit. 2; H319: 5 % ≤ C < 25 % B, D, F 605-002-00-0 1,3,5-trioxan; trioxymethylene 203-812-5 110-88-3 Flam. Sol. 1 Repr. 2 STOT SE 3 H228 … 310 unchanged lines … 31906-04-4 [2] 51414-25-6 [3] Skin Sens. 1A H317 GHS07 Wng H317 605-041-00-3 2-(4-tert-butylbenzyl)propionaldehyde 201-289-8 80-54-6 Repr. 1B H360Fd GHS08 Dgr H360Fd 606-001-00-8 acetone; propan-2-one; propanone 200-662-2 67-64-1 Flam. Liq. 2 Dgr H360Fd 605-042-00-9 α-methyl-1,3-benzodioxole-5-propionaldehyde [1] (S)-α-methyl-1,3-benzodioxole-5-propionaldehyde; (2S)-3-(1,3-benzodioxol-5-yl)-2-methylpropanal [2] (R)-α-methyl-1,3-benzodioxole-5-propionaldehyde; (2R)-3-(1,3-benzodioxol-5-yl)-2-methylpropanal [3] 214-881-6 [1] - [2] - [3] 1205-17-0 [1] 737776-68-0 [2] 737776-59-9 [3] Skin Sens. 1B H317 GHS07 Wng H317 605-043-00-4 2,4-dimethylcyclohex-3-ene-1-carbaldehyde [1] (1α,2α,5α)-2,5-dimethylcyclohex-3-ene-1-carbaldehyde [2] 2,6-dimethylcyclohex-3-ene-1-carbaldehyde [3] 3,5-dimethylcyclohex-3-ene-1-carbaldehyde [4] 3,6-dimethylcyclohex-3-ene-1-carbaldehyde [5] 4,6-dimethylcyclohex-3-ene-1-carbaldehyde [6] reaction mass of 3,5-dimethylcyclohex-3-ene-1-carbaldehyde and 2,4-dimethylcyclohex-3-ene-1-carbaldehyde [7] dimethylcyclohex-3-ene-1-carbaldehyde [8] Dimethylcyclohex-3-ene-1-carbaldehyde [9] 1,2,4(or 1,3,5)-trimethylcyclohex-3-ene-1-carbaldehyde [10] 1,3,4-trimethylcyclohex-3-ene-1-carbaldehyde [11] 2,2,4-trimethylcyclohex-3-ene-1-carbaldehyde [12] 2,4,6-trimethylcyclohex-3-enecarbaldehyde [13] isocyclocitral [14] 3,5,6-trimethylcyclohex-3-ene-1-carbaldehyde [15] 4,6,6-trimethylcyclohex-3-ene-1-carbaldehyde [16] 268-264-1 [1] 252-395-6 [2] - [3] 268-263-6 [4] 267-186-5 [5] 253-139-6 [6] - [7] 248-742-6 [8] 272-113-5 [9] 276-055-1 [10] - [11] - [12] 215-833-7 [13] 215-638-7 [14] 266-810-3 [15] - [16] 68039-49-6 [1] 35145-02-9 [2] 6975-94-6 [3] 68039-48-5 [4] 67801-65-4 [5] 36635-35-5 [6] - [7] 27939-60-2 [8] 68737-61-1 [9] 71832-78-5 [10] 40702-26-9 [11] 1726-47-2 [12] 1423-46-7 [13] 1335-66-6 [14] 67634-07-5 [15] 6754-27-4 [16] Skin Sens. 1 H317 GHS07 Wng H317 606-001-00-8 acetone; propan-2-one; propanone 200-662-2 67-64-1 Flam. Liq. 2 Eye Irrit. 2 STOT SE 3 H225 H319 … 870 unchanged lines … M = 10 606-155-00-6 cinnamaldehyde; 3-phenylprop-2-enal; cinnamic aldehyde; cinnamal; [1] (2E)-3-phenylprop-2-enal [2] 203-213-9 [1] - [2] 104-55-2 [1] 14371-10-9 [2] Skin Sens. 1A H317 GHS07 Wng H317 Skin Sens. 1A; H317: C ≥ 0,01 % 607-001-00-0 formic acid … % 200-579-1 64-18-6 Skin Corr. 1A H314 GHS05 Dgr H314 Skin Corr. 1A; H314: C ≥ 90 % Skin Corr. 1B; H314: 10 % ≤ C < 90 % Skin Irrit. 2; H315: 2 % ≤C < 10 % Eye Irrit. 2; H319: 2 %≤ <10 % B Wng H317 Skin Sens. 1A; H317: C ≥ 0,01 % 606-157-00-7 (3E)-dec-3-en-2-one — 18402-84-1 Acute Tox. 4 Asp. Tox. 1 Skin Irrit. 2 Aquatic Chronic 2 H332 H304 H315 H411 GHS07 GHS08 GHS09 Dgr H332 H304 H315 H411 EUH071 inhalation: ATE = 1,5 mg/L (dusts or mists) 606-158-00-2 2-(dimethylamino)-2-[(4-methylphenyl)methyl]-1-[4-(morpholin-4-yl)phenyl]butan-1-one 438-340-0 119344-86-4 Repr. 1B Aquatic Acute 1 Aquatic Chronic 1 H360Df H400 H410 GHS08 GHS09 Dgr H360Df H410 M = 1 M = 1 607-001-00-0 formic acid … % 200-579-1 64-18-6 Flam. Liq. 3 Met. Corr. 1 Acute Tox. 3 Acute Tox. 4 Skin Corr. 1A Eye Dam. 1 H226 H290 H331 H302 H314 H318 GHS02 GHS05 GHS06 Dgr H226 H290 H331 H302 H314 EUH071 inhalation: ATE = 7,4 mg/L (vapours) oral: ATE = 500 mg/kg bw Flam. Liq. 3; H226: C > 85 % Skin Corr. 1A; H314: C ≥ 90 % Skin Corr. 1B; 314: 10 % ≤ C < 90 % Skin Irrit. 2; H315: 2 % ≤ C < 10 % Eye Dam. 1; H318: C ≥ 10 % Eye Irrit. 2; H319: 2 % ≤ C < 10 % B 607-002-00-6 acetic acid … % 200-580-7 64-19-7 Flam. Liq. 3 Skin Corr. 1A H226 H314 GHS02 … 412 unchanged lines … H335 H315 H410 A 607-043-00-X dicamba (ISO); 2,5-dichloro-6-methoxybenzoic acid; 3,6-dichloro-2-methoxybenzoic acid 217-635-6 1918-00-9 Acute Tox. 4 * 607-043-00-X dicamba (ISO); 2,5-dichloro-6-methoxybenzoic acid; 3,6-dichloro-2-methoxybenzoic acid 217-635-6 1918-00-9 Acute Tox. 4 Acute Tox. 4 STOT SE 3 STOT SE 3 Eye Dam. 1 Aquatic Chronic 3 H302 Aquatic Acute 1 Aquatic Chronic 2 H332 H302 H335 H336 H318 H412 GHS05 GHS07 Dgr H302 H400 H411 GHS07 GHS05 GHS09 Dgr H332 H302 H335 H336 H318 H412 607-044-00-5 3,6-dichloro-o-anisic acid, compound with dimethylamine (1:1); [1] potassium 3,6-dichloro-o-anisate[2] 218-951-7 [1] H410 inhalation: ATE = 4,0 mg/L (dusts or mists) oral: ATE = 1500 mg/kg bw M = 1 607-044-00-5 3,6-dichloro-o-anisic acid, compound with dimethylamine (1:1); [1] potassium 3,6-dichloro-o-anisate[2] 218-951-7 [1] 233-002-7 [2] 2300-66-5 [1] 10007-85-9 [2] Eye Irrit. 2 Aquatic Chronic 3 H319 … 442 unchanged lines … GHS05 Dgr H225 H314 EUH014 B D 607-094-00-8 peracetic acid . . . % 201-186-8 79-21-0 Flam. Liq. 3 Org. Perox. D **** Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Skin Corr. 1A Aquatic Acute 1 H226 H242 H332 H312 H302 607-094-00-8 peracetic acid … % 201-186-8 79-21-0 Org. Perox. D Acute Tox. 2 Acute Tox. 2 Acute Tox. 3 Skin Corr. 1A Aquatic Acute 1 Aquatic Chronic 1 H242 H330 H310 H301 H314 H400 GHS02 H400 H410 GHS02 GHS06 GHS05 GHS07 GHS09 Dgr H226 H242 H332 H312 H302 Dgr H242 H330 H310 H301 H314 H400 * STOT SE 3; H335: C ≥ 1 % B D H410 EUH071 inhalation: ATE = 0,2 mg/L (dusts or mists) dermal: ATE = 60 mg/kg bw oral: ATE = 80 mg/kg bw STOT SE 3; H335: C ≥ 1 % M = 10 M = 100 B, D, T 607-095-00-3 maleic acid 203-742-5 110-16-7 Acute Tox. 4 * Eye Irrit. 2 STOT SE 3 … 811 unchanged lines … H412 GHS07 Wng H315 H319 H412 607-198-00-3 propyl 3,4,5-trihydroxybenzoate 204-498-2 121-79-9 Acute Tox. 4 * Skin Sens. 1 H302 H317 GHS07 H412 607-198-00-3 propyl 3,4,5-trihydroxybenzoate 204-498-2 121-79-9 Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H302 H317 H400 H410 GHS07 GHS09 Wng H302 H317 607-199-00-9 octyl 3,4,5-trihydroxybenzoate 213-853-0 1034-01-1 Acute Tox. 4 * H317 H410 oral: ATE = 1700 mg/kg bw M = 1 M = 1 607-199-00-9 octyl 3,4,5-trihydroxybenzoate 213-853-0 1034-01-1 Acute Tox. 4 * Skin Sens. 1 H302 H317 GHS07 Wng H302 … 1,428 unchanged lines … GHS09 Dgr H331 H302 H410 607-432-00-4 S-metolachlor; reaction mass of (S)-2-chloro-N-(2-ethyl-6-methyl-phenyl)-N-(2-methoxy-1-methyl-ethyl)-acetamide (80-100 %); [1] (R)-2-chloro-N-(2-ethyl-6-methyl-phenyl)-N-(2-methoxy-1-methyl-ethyl)-acetamide (0-20 %) [2] -[1] -[2] 87392-12-9 [1] 178961-20-1 [2] Skin Sens. 1 H410 607-432-00-4 S-metolachlor (ISO); 2-chloro-N-(2-ethyl-6-methylphenyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide; (RaSa)-2-chloro-N-(6-ethyl-o-tolyl)-N-[(1S)-2-methoxy-1-methylethyl]acetamide [contains 80-100 % 2-chloro-N-(2-ethyl-6-methylphenyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide and 0-20 % 2-chloro-N-(2-ethyl-6-methylphenyl)-N-[(2R)-1-methoxypropan-2-yl]acetamide] — 87392-12-9 Carc. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H317 Aquatic Chronic 1 H351 H317 H400 H410 GHS07 H410 GHS08 GHS07 GHS09 Wng H317 H410 607-433-00-X cypermethrin cis/trans +/-80/20; (RS)-α-cyano-3-phenoxybenzyl (1RS;3RS; 1RS, 3SR)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate 257-842-9 52315-07-8 Acute Tox. 4 * STOT SE 3 Wng H351 H317 H410 EUH066 M = 10 M = 10 607-433-00-X cypermethrin cis/trans +/-80/20; (RS)-α-cyano-3-phenoxybenzyl (1RS;3RS; 1RS, 3SR)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate 257-842-9 52315-07-8 Acute Tox. 4 * STOT SE 3 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 … 1,739 unchanged lines … H410 oral: ATE = 1500 mg/kg bw M = 1000 M = 1000 608-001-00-3 acetonitrile; cyanomethane 200-835-2 75-05-8 Flam. Liq. 2 M = 1000 607-770-00-2 2,3-epoxypropyl neodecanoate 247-979-2 26761-45-5 Muta. 2 Skin Sens. 1A H341 H317 GHS08 GHS07 Wng H341 H317 Skin Sens. 1A; H317: C ≥ 0,001 % 607-771-00-8 benthiavalicarb-isopropyl (ISO); isopropyl [(S)-1-{[(R)-1-(6-fluoro-1,3-benzothiazol-2-yl)ethyl]carbamoyl}-2-methylpropyl]carbamate — 177406-68-7 Carc. 1B Repr. 2 Skin Sens. 1 Aquatic Chronic 2 H350 H361fd H317 H411 GHS08 GHS07 GHS09 Dgr H350 H361fd H317 H411 607-772-00-3 hexyl salicylate 228-408-6 6259-76-3 Repr. 2 Skin Sens. 1 H361d H317 GHS08 GHS07 Wng H361d H317 607-773-00-9 7-oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate 219-207-4 2386-87-0 Muta. 2 STOT RE 2 Skin Sens. 1 H341 H373 (nasal cavity) H317 GHS08 GHS07 Wng H341 H373 (nasal cavity) H317 607-774-00-4 tetrasodium 4-amino-5-hydroxy-3,6-bis[[4-[[2-(sulphonatooxy)ethyl]sulphonyl]phenyl]azo]naphthalene-2,7-disulphonate [1] Reaction products of 4-amino-5-hydroxynaphthalene-2,7-disulfonic acid, coupled twice with diazotized 2-[(4-aminophenyl)sulfonyl]ethyl hydrogen sulfate, sodium salts [2] disodium 4-amino-5-hydroxy-3,6-bis{[4-(vinylsulfonyl) phenyl]diazenyl}naphthalene-2,7-disulfonate [3] 241-164-5 [1] - [2] - [3] 17095-24-8 [1] - [2] 100556-82-9 [3] Resp. Sens. 1A Skin Sens. 1 H334 H317 GHS08 Dgr H334 H317 607-775-00-X Sodium 3-(allyloxy)-2-hydroxypropanesulphonate 258-004-5 52556-42-0 Repr. 1B Eye Dam. 1 H360F H318 GHS08 GHS05 Dgr H360F H318 608-001-00-3 acetonitrile; cyanomethane 200-835-2 75-05-8 Flam. Liq. 2 Acute Tox. 4 * Acute Tox. 4 * Acute Tox. 4 * Eye Irrit. 2 H225 H332 … 1,535 unchanged lines … H302 H317 H412 609-073-00-9 lithium potassium sodium N,N''-bis{6-[7-[4-(4-chloro-1,3,5-triazin-2-yl)amino-4-(2-ureidophenylazo)]naphthalene-1,3,6-trisulfonato}-N'-(2-aminoethyl)piperazine 427-850-9 — Skin Sens. 1 H317 GHS07 Wng H317 610-001-00-3 trichloronitromethane; Wng H317 609-074-00-4 1,4-dichloro-2-nitrobenzene 201-923-3 89-61-2 Carc. 1B H350 GHS08 Dgr H350 610-001-00-3 trichloronitromethane; chloropicrin 200-930-9 76-06-2 Acute Tox. 2 * Acute Tox. 4 * Eye Irrit. 2 … 1,021 unchanged lines … H373 (liver) H315 H318 H411 oral: ATE = 136 mg/kg bw 612-001-00-9 mono-methylamine; [1] H411 oral: ATE = 136 mg/kg bw 611-182-00-1 2-[ethyl[3-methyl-4-[(5-nitrothiazol-2-yl)azo]phenyl]amino]ethanol 271-183-4 68516-81-4 Skin Sens. 1A H317 GHS07 Wng H317 Skin Sens. 1A; H317: C ≥ 0,001 % 612-001-00-9 mono-methylamine; [1] di-methylamine; [2] tri-methylamine [3] 200-820-0 [1] 204-697-4 [2] … 3,599 unchanged lines … H317 GHS08 GHS07 Dgr H360FD H317 613-001-00-1 ethyleneimine; aziridine 205-793-9 151-56-4 Flam. Liq. 2 H317 612-299-00-0 fenpropidin (ISO); (R,S)-1-[3-(4-tert-butylphenyl)-2-methylpropyl]piperidine — 67306-00-7 Repr. 2 Acute Tox. 4 Acute Tox. 4 STOT SE 3 STOT SE 3 STOT RE 2 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H361d H332 H302 H335 H336 H373 (nervous system, eyes, lungs) H315 H318 H317 H400 H410 GHS08 GHS07 GHS05 GHS09 Dgr H361d H332 H302 H335 H336 H373 (nervous system, eyes, lungs) H315 H318 H317 H410 Inhalation: ATE = 1,2 mg/L (dusts or mists) oral: ATE = 1330 mg/kg bw M = 1000 M = 10000 613-001-00-1 ethyleneimine; aziridine 205-793-9 151-56-4 Flam. Liq. 2 Carc. 1B Muta. 1B Acute Tox. 2 * … 2,219 unchanged lines … H410 GHS07 GHS09 Wng H317 H410 M=10 613-272-00-6 pyraclostrobin (ISO); methyl N-{2-[1-(4-chlorophenyl)-1H-pyrazol-3-yloxymethyl]phenyl}(N-methoxy)carbamate — — Acute Tox. 3 * H410 M=10 613-272-00-6 pyraclostrobin (ISO); methyl N-(2-{[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxymethyl}phenyl) N-methoxy carbamate — 175013-18-0 Repr. 2 Acute Tox. 3 Acute Tox. 4 STOT SE 3 STOT RE 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 H331 Aquatic Chronic 1 H361d H331 H302 H335 H373 (liver, gastrointestinal tract, nasal cavity) H315 H400 H410 GHS06 H410 GHS08 GHS06 GHS09 Dgr H331 Dgr H361d H331 H302 H335 H373 (liver, gastrointestinal tract, nasal cavity) H315 H410 M=100 613-273-00-1 tetrahydro-3-methyl-5-((2-phenylthio)thiazol-5-ylmethyl)-[4H]-1,3,5-oxadiazinan-4-ylidene-N-nitroamine 427-600-9 192439-46-6 Aquatic Chronic 2 H411 GHS09 H411 613-274-00-7 2,6-dichloro-1-fluoropyridiniumtetrafluoroborate 427-400-1 140623-89-8 Skin Corr. 1B H410 inhalation: ATE = 0,58 mg/L (dusts or mists) oral: ATE = 450 mg/kg bw M = 100 M = 100 613-273-00-1 tetrahydro-3-methyl-5-((2-phenylthio)thiazol-5-ylmethyl)-[4H]-1,3,5-oxadiazinan-4-ylidene-N-nitroamine 427-600-9 192439-46-6 Aquatic Chronic 2 H411 GHS09 H411 613-274-00-7 2,6-dichloro-1-fluoropyridiniumtetrafluoroborate 427-400-1 140623-89-8 Skin Corr. 1B Acute Tox. 4 * Skin Sens. 1 Aquatic Acute 1 … 732 unchanged lines … Repr. 1B H350 H360Fd GHS08 Dgr H350 H360Fd 614-001-00-4 nicotine (ISO); H360Fd 613-350-00-X 1H-benzotriazole 202-394-1 95-14-7 Aquatic Chronic 2 H411 GHS09 Wng H411 613-351-00-5 methyl-1H-benzotriazole 249-596-6 29385-43-1 Aquatic Chronic 2 H411 GHS09 Wng H411 614-001-00-4 nicotine (ISO); 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine 200-193-3 54-11-5 Acute Tox. 2 Acute Tox. 2 Acute Tox. 2 … 1,503 unchanged lines … GHS07 Wng H302 H373** H412 616-127-00-5 reaction mass of: N, N'-Ethane-1,2-diylbis(decanamide); 12-Hydroxy-N-[2-[1-oxydecyl)amino]ethyl]octadecanamide; N, N'-Ethane-1,2-diylbis(12hydroxyoctadecanamide) 430-050-2 — Skin Sens. 1 Aquatic Chronic 2 H317 H411 GHS07 H412 616-127-00-5 reaction mass of N,N'-ethane-1,2-diylbis(decanamide) and 12-hydroxy-N-[2-[(1-oxodecyl)amino]ethyl]octadecanamide and N,N'-ethane-1,2-diylbis(12-hydroxyoctadecanamide) [1] reaction mass of N,N'-ethane-1,2-diylbis(decanamide) and 12-hydroxy-N-[2-[(1-oxodecyl)amino]ethyl]octadecanamide [2] 430-050-2 [1] - [2] - [1] - [2] Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H317 H400 H410 GHS07 GHS09 Wng H317 H411 616-128-00-0 N-(2-(1-allyl-4,5-dicyanoimidazol-2-ylazo)-5-(dipropylamino)phenyl)-acetamide 417-530-7 123590-00-1 Aquatic Chronic 4 H413 — H413 616-129-00-6 N,N'-bis(2,2,6,6-tetramethyl-4-piperidyl)isophthalamide 419-710-0 42774-15-2 Acute Tox. 4 * H410 M = 100 M = 10 616-128-00-0 N-(2-(1-allyl-4,5-dicyanoimidazol-2-ylazo)-5-(dipropylamino)phenyl)-acetamide 417-530-7 123590-00-1 Aquatic Chronic 4 H413 — H413 616-129-00-6 N,N'-bis(2,2,6,6-tetramethyl-4-piperidyl)isophthalamide 419-710-0 42774-15-2 Acute Tox. 4 * Eye Irrit. 2 H302 H319 GHS07 Wng H302 … 590 unchanged lines … GHS09 Wng H373 (blood system, thyroid) H410 M = 1000 M = 1000 617-001-00-2 di-tert-butyl peroxide 203-733-6 110-05-4 Org. Perox. E Flam. Liq. 2 Muta. 2 H242 M = 1000 616-243-00-6 N,N'-methylenediacrylamide 203-750-9 110-26-9 Muta. 1B H340 GHS08 Dgr H340 617-001-00-2 di-tert-butyl peroxide 203-733-6 110-05-4 Org. Perox. E Flam. Liq. 2 Muta. 2 H242 H225 H341 GHS02 GHS08 … 70 unchanged lines … GHS09 Wng H242 H315 H411 617-008-00-0 dibenzoyl peroxide; benzoyl peroxide 202-327-6 94-36-0 Org. Perox. B H411 617-008-00-0 dibenzoyl peroxide; benzoyl peroxide 202-327-6 94-36-0 Org. Perox. B Eye Irrit. 2 Skin Sens. 1 H241 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H241 H319 H317 GHS01 H317 H400 H410 GHS01 GHS02 GHS07 GHS09 Dgr H241 H319 H317 617-010-00-1 1-hydroperoxycyclohexyl 1-hydroxycyclohexyl peroxide; [1] H317 H410 M = 10 M = 10 617-010-00-1 1-hydroperoxycyclohexyl 1-hydroxycyclohexyl peroxide; [1] 1,1’-dioxybiscyclohexan-1-ol; [2] cyclohexylidene hydroperoxide; [3] cyclohexanone, peroxide [4] 201-091-1 [1] … 139 unchanged lines … H314 H317 H411 617-023-00-2 tert-butyl hydroperoxide 200-915-7 75-91-2 Muta. 2 H341 GHS08 Wng H341 647-001-00-8 glucosidase, β- 232-589-7 9001-22-3 Resp. Sens. 1 H334 GHS08 Wng H341 617-024-00-8 tert-butyl 2-ethylperoxyhexanoate 221-110-7 3006-82-4 Repr. 1B Skin Sens. 1 H360FD H317 GHS08 GHS07 Dgr H360FD H317 647-001-00-8 glucosidase, β- 232-589-7 9001-22-3 Resp. Sens. 1 H334 GHS08 Dgr H334 647-002-00-3 cellulase 232-734-4 9012-54-8 Resp. Sens. 1 H334 GHS08 Dgr H334 647-003-00-9 cellobiohydrolase, exo- 253-465-9 37329-65-0 Resp. Sens. 1 H334 GHS08 Dgr H334 647-004-00-4 cellulases with the exception of those specified elsewhere in this Annex — — Resp. Sens. 1 H334 GHS08 … 24,737 unchanged lines … S: 61 650-055-00-5 silver sodium zirconium hydrogenphosphate 422-570-3 155925-27-2 N; R50-53 N R: 50/53 S: 60-61